India · Delayed Price · Currency is INR Ipca Laboratories Earnings Call Transcripts
Fiscal Year 2026
-
Q4 FY26 saw 12% domestic growth and 8% consolidated revenue growth, with EBITDA margins exceeding guidance. FY27 outlook is for 12%-13% revenue growth and margin improvement, despite raw material and freight cost pressures.
-
Q3 saw 6.5% revenue growth and improved EBITDA margins, with strong domestic and export performance, especially in chronic therapies and West Africa. Unichem margins remain under pressure but are expected to recover as new launches and filings mature.
-
Domestic and API businesses delivered strong growth, with EBITDA margins improving year-over-year. Export formulations declined but are expected to recover in H2, while Unichem's performance is stabilizing post-restructuring. R&D spend is rising, supporting a robust pipeline.
-
Domestic and export businesses delivered double-digit growth, with strong gains in chronic and acute segments. Standalone margins improved, but consolidated EBITDA margin guidance was trimmed due to Unichem's challenges, including one-time provisions and market share losses.
Fiscal Year 2025
-
Domestic and export businesses delivered double-digit growth, with significant margin expansion and improved market share, especially in chronic therapies. CapEx and new plant investments are set to drive future growth, while Unichem integration and export market recovery are expected to enhance performance.
-
EBITDA margins and gross margins reached record highs, driven by improved product mix, strong chronic and pain management growth, and operational gains from Unichem integration. Domestic business outperformed the market, while API and EU generics showed solid growth.
-
Domestic and export formulation businesses delivered double-digit growth, with EBITDA margins improving year-over-year due to better product mix and cost controls. Guidance for FY25 margins was raised, while revenue growth was slightly moderated; Unichem integration and US launches are expected to drive future growth.
-
Domestic business drove double-digit growth and market share gains, while exports and API faced headwinds from logistics and supply chain issues. Margins exceeded guidance, and full-year profitability is expected to surpass earlier projections despite a downward revision in revenue growth.